Pharmaceutical Mergers and Acquisitions: What You Need to Know
Stay informed about the latest in drug development with BioPharma Dive’s free newsletter, delivered straight to your inbox. In the […]
Stay informed about the latest in drug development with BioPharma Dive’s free newsletter, delivered straight to your inbox. In the […]
Xoma Royalty Corp. has agreed to buy Mural Oncology, a biotech company focused on cancer treatments, for $2.035 per share.
The obesity drug market is currently dominated by two major players: Eli Lilly and Novo Nordisk. Both companies are working
Over the next five years, many top-selling cancer drugs from major pharmaceutical companies will lose their patent protection. This is
A report from the Make America Healthy Again (MAHA) Commission was delayed earlier this month, but leaked documents reveal plans
Measuring how long a cancer treatment extends life (overall survival, or OS) is the best way to judge its effectiveness.
The US Food and Drug Administration (FDA) has given special recognition to a new experimental drug called izalontamab brengitecan (iza-bren).
Gilead’s Kite Pharma has agreed to purchase Interius BioTherapeutics for $350 million. This deal will help Kite expand its work
Anne White, the Executive Vice President and President of Lilly Neuroscience at Eli Lilly and Company, will retire at the
Eli Lilly is looking for a new leader for its neuroscience division after announcing that Anne White, the current head,